Cargando…

Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report

Epithelioid hemangioendotheliomas (EHEs), low-grade malignant tumors of vascular endothelial cell origin, are characterized by vascular endothelial proliferation. In 2002, the World Health Organization classified EHEs as locally aggressive tumors with the potential to metastasize. Currently, the dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Yuqing, Peng, Lili, Liu, Miaomiao, He, Liya, Wang, Fayan, Li, Bingjie, Niu, Xueliang, Zhang, Hongzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063782/
https://www.ncbi.nlm.nih.gov/pubmed/37006308
http://dx.doi.org/10.3389/fimmu.2023.1116944
_version_ 1785017767199506432
author Bu, Yuqing
Peng, Lili
Liu, Miaomiao
He, Liya
Wang, Fayan
Li, Bingjie
Niu, Xueliang
Zhang, Hongzhen
author_facet Bu, Yuqing
Peng, Lili
Liu, Miaomiao
He, Liya
Wang, Fayan
Li, Bingjie
Niu, Xueliang
Zhang, Hongzhen
author_sort Bu, Yuqing
collection PubMed
description Epithelioid hemangioendotheliomas (EHEs), low-grade malignant tumors of vascular endothelial cell origin, are characterized by vascular endothelial proliferation. In 2002, the World Health Organization classified EHEs as locally aggressive tumors with the potential to metastasize. Currently, the diagnosis of EHE is based on pathology, histological and immunohistochemical examinations. There are no standard treatment guidelines. We here report a 69-year-old man who presented with left-sided chest and abdominal pain for more than 2 months. Enhanced computed tomography of the thorax and abdomen in another hospital suggested a mass in the left adrenal region that was considered malignant. Positron emission tomography- computed tomography in our hospital suggested a large multi-loculated, hypermetabolic, cystic mass in the left adrenal region that was considered malignant. Accordingly, a puncture biopsy of the mass was performed and the diagnosis of EHE confirmed by pathological examination, including immunohistochemical staining. This patient was treated with the programmed death 1 (PD-1) immune checkpoint inhibitor toripalimab with long-term success. The best response was stable disease (SD) with a progression-free survival (PFS) of more than 13 months. The patient is still alive now. Because the sample size of previous studies was small, further studies are needed to determine the safety and efficacy of toripalimab in the treatment of EHE.
format Online
Article
Text
id pubmed-10063782
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100637822023-04-01 Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report Bu, Yuqing Peng, Lili Liu, Miaomiao He, Liya Wang, Fayan Li, Bingjie Niu, Xueliang Zhang, Hongzhen Front Immunol Immunology Epithelioid hemangioendotheliomas (EHEs), low-grade malignant tumors of vascular endothelial cell origin, are characterized by vascular endothelial proliferation. In 2002, the World Health Organization classified EHEs as locally aggressive tumors with the potential to metastasize. Currently, the diagnosis of EHE is based on pathology, histological and immunohistochemical examinations. There are no standard treatment guidelines. We here report a 69-year-old man who presented with left-sided chest and abdominal pain for more than 2 months. Enhanced computed tomography of the thorax and abdomen in another hospital suggested a mass in the left adrenal region that was considered malignant. Positron emission tomography- computed tomography in our hospital suggested a large multi-loculated, hypermetabolic, cystic mass in the left adrenal region that was considered malignant. Accordingly, a puncture biopsy of the mass was performed and the diagnosis of EHE confirmed by pathological examination, including immunohistochemical staining. This patient was treated with the programmed death 1 (PD-1) immune checkpoint inhibitor toripalimab with long-term success. The best response was stable disease (SD) with a progression-free survival (PFS) of more than 13 months. The patient is still alive now. Because the sample size of previous studies was small, further studies are needed to determine the safety and efficacy of toripalimab in the treatment of EHE. Frontiers Media S.A. 2023-03-17 /pmc/articles/PMC10063782/ /pubmed/37006308 http://dx.doi.org/10.3389/fimmu.2023.1116944 Text en Copyright © 2023 Bu, Peng, Liu, He, Wang, Li, Niu and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Bu, Yuqing
Peng, Lili
Liu, Miaomiao
He, Liya
Wang, Fayan
Li, Bingjie
Niu, Xueliang
Zhang, Hongzhen
Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
title Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
title_full Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
title_fullStr Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
title_full_unstemmed Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
title_short Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
title_sort epithelioid hemangioendothelioma of the retroperitoneal giant type treated with toripalimab: a case report
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063782/
https://www.ncbi.nlm.nih.gov/pubmed/37006308
http://dx.doi.org/10.3389/fimmu.2023.1116944
work_keys_str_mv AT buyuqing epithelioidhemangioendotheliomaoftheretroperitonealgianttypetreatedwithtoripalimabacasereport
AT penglili epithelioidhemangioendotheliomaoftheretroperitonealgianttypetreatedwithtoripalimabacasereport
AT liumiaomiao epithelioidhemangioendotheliomaoftheretroperitonealgianttypetreatedwithtoripalimabacasereport
AT heliya epithelioidhemangioendotheliomaoftheretroperitonealgianttypetreatedwithtoripalimabacasereport
AT wangfayan epithelioidhemangioendotheliomaoftheretroperitonealgianttypetreatedwithtoripalimabacasereport
AT libingjie epithelioidhemangioendotheliomaoftheretroperitonealgianttypetreatedwithtoripalimabacasereport
AT niuxueliang epithelioidhemangioendotheliomaoftheretroperitonealgianttypetreatedwithtoripalimabacasereport
AT zhanghongzhen epithelioidhemangioendotheliomaoftheretroperitonealgianttypetreatedwithtoripalimabacasereport